767 related articles for article (PubMed ID: 26073325)
1. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
2. The Putative Role of Natural Killer Cells in Patients with Hepatitis C Virus-Related Hepatocellular Carcinoma.
Hassouna MM; Radwan EM; Abdelsameea E; Estaphan S; Abd Elrhman HE; Abdel-Samiee M; Naguib M
Asian Pac J Cancer Prev; 2021 Aug; 22(8):2559-2567. PubMed ID: 34452571
[TBL] [Abstract][Full Text] [Related]
3. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma.
Sun C; Sun H; Zhang C; Tian Z
Cell Mol Immunol; 2015 May; 12(3):292-302. PubMed ID: 25308752
[TBL] [Abstract][Full Text] [Related]
4. Natural Killer Cells and T Cells in Hepatocellular Carcinoma and Viral Hepatitis: Current Status and Perspectives for Future Immunotherapeutic Approaches.
Kalathil SG; Thanavala Y
Cells; 2021 May; 10(6):. PubMed ID: 34071188
[TBL] [Abstract][Full Text] [Related]
5. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
6. hIL-15 gene-modified human natural killer cells (NKL-IL15) augments the anti-human hepatocellular carcinoma effect in vivo.
Jiang W; Zhang C; Tian Z; Zhang J
Immunobiology; 2014 Jul; 219(7):547-53. PubMed ID: 24721706
[TBL] [Abstract][Full Text] [Related]
7. Energy metabolism and cell motility defect in NK-cells from patients with hepatocellular carcinoma.
Zecca A; Barili V; Canetti D; Regina V; Olivani A; Carone C; Capizzuto V; Zerbato B; Trenti T; Dalla Valle R; Ferrari C; Cariani E; Missale G
Cancer Immunol Immunother; 2020 Aug; 69(8):1589-1603. PubMed ID: 32307580
[TBL] [Abstract][Full Text] [Related]
8. The pathogenesis of hepatocellular carcinoma is multifactorial event. Novel immunological treatment in prospect.
Marotta F; Vangieri B; Cecere A; Gattoni A
Clin Ter; 2004 May; 155(5):187-99. PubMed ID: 15344567
[TBL] [Abstract][Full Text] [Related]
9. Diminished absolute counts of CD56dim and CD56bright natural killer cells in peripheral blood from Egyptian patients with hepatocellular carcinoma.
Fathy A; Eldin MM; Metwally L; Eida M; Abdel-Rehim M
Egypt J Immunol; 2009; 16(2):17-25. PubMed ID: 22059350
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis virus infection affects DNA methylation in mice with humanized livers.
Okamoto Y; Shinjo K; Shimizu Y; Sano T; Yamao K; Gao W; Fujii M; Osada H; Sekido Y; Murakami S; Tanaka Y; Joh T; Sato S; Takahashi S; Wakita T; Zhu J; Issa JP; Kondo Y
Gastroenterology; 2014 Feb; 146(2):562-72. PubMed ID: 24184133
[TBL] [Abstract][Full Text] [Related]
11. NK cells in hepatitis B virus infection: a potent target for immunotherapy.
Shabani Z; Bagheri M; Zare-Bidaki M; Hassanshahi G; Arababadi MK; Mohammadi Nejad M; Kennedy D
Arch Virol; 2014 Jul; 159(7):1555-65. PubMed ID: 24445811
[TBL] [Abstract][Full Text] [Related]
12. Natural Killer Cell Dysfunction in Hepatocellular Carcinoma: Pathogenesis and Clinical Implications.
Sung PS; Jang JW
Int J Mol Sci; 2018 Nov; 19(11):. PubMed ID: 30463262
[TBL] [Abstract][Full Text] [Related]
13. Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy.
Liu P; Chen L; Zhang H
J Immunol Res; 2018; 2018():1206737. PubMed ID: 30255103
[TBL] [Abstract][Full Text] [Related]
14. RAC1
Shi X; Chen W; Yin Y; Cao H; Wang X; Jiang W; Li Q; Li X; Yu Y; Wang X
Cancer Lett; 2024 Jun; 592():216909. PubMed ID: 38679407
[TBL] [Abstract][Full Text] [Related]
15. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.
Cui J; Wang N; Zhao H; Jin H; Wang G; Niu C; Terunuma H; He H; Li W
Int J Cancer; 2014 Jan; 134(2):342-51. PubMed ID: 23825037
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells in hepatocellular carcinoma: current status and perspectives for future immunotherapeutic approaches.
Yu M; Li Z
Front Med; 2017 Dec; 11(4):509-521. PubMed ID: 28780700
[TBL] [Abstract][Full Text] [Related]
17. Dual Effects of Cellular Immunotherapy in Inhibition of Virus Replication and Prolongation of Survival in HCV-Positive Hepatocellular Carcinoma Patients.
Qian L; Wang N; Tian H; Jin H; Zhao H; Niu C; He H; Ge T; Han W; Hu J; Li D; Han F; Xu J; Ding X; Chen J; Li W; Cui J
J Immunol Res; 2016; 2016():6837241. PubMed ID: 27069936
[TBL] [Abstract][Full Text] [Related]
18. Kbtbd2 inhibits the cytotoxic activity of immortalized NK cells through down-regulating mTOR signaling in a mouse hepatocellular carcinoma model.
Dai K; Huang Y; Chen Z; Sun X; Yang L; Jiang Y
Eur J Immunol; 2018 Apr; 48(4):683-695. PubMed ID: 29331106
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin enhances NK cells immunotherapy efficacy to suppress HCC progression via altering the androgen receptor (AR)-ULBP2 signals.
Shi L; Lin H; Li G; Sun Y; Shen J; Xu J; Lin C; Yeh S; Cai X; Chang C
Cancer Lett; 2016 Apr; 373(1):45-56. PubMed ID: 26805759
[TBL] [Abstract][Full Text] [Related]
20. Natural Killer Cell Expansion with Autologous Feeder Layer and Anti-CD3 Antibody for Immune Cell Therapy of Hepatocellular Carcinoma.
Hosseinzadeh F; Ai J; Ebrahimi-Barough S; Seyhoun I; Hajifathali A; Muhammadnejad S; Hosseinzadeh F; Shadnoush M; Dabiri Oskouei F; Verdi J
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3797-3803. PubMed ID: 31870124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
